Zoetis Inc. $ZTS Shares Sold by Bailard Inc.

Bailard Inc. decreased its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 2.2% during the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 64,144 shares of the company’s stock after selling 1,425 shares during the quarter. Bailard Inc.’s holdings in Zoetis were worth $10,003,000 as of its most recent SEC filing.

Other institutional investors have also recently added to or reduced their stakes in the company. Nuveen LLC purchased a new stake in Zoetis in the 1st quarter valued at about $616,375,000. Mitsubishi UFJ Asset Management Co. Ltd. boosted its position in shares of Zoetis by 113.0% in the second quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 3,761,920 shares of the company’s stock worth $586,671,000 after acquiring an additional 1,995,491 shares during the last quarter. Mackenzie Financial Corp boosted its position in shares of Zoetis by 4,158.3% in the first quarter. Mackenzie Financial Corp now owns 1,824,967 shares of the company’s stock worth $300,481,000 after acquiring an additional 1,782,110 shares during the last quarter. Polen Capital Management LLC grew its holdings in Zoetis by 17.6% in the first quarter. Polen Capital Management LLC now owns 8,796,847 shares of the company’s stock valued at $1,448,401,000 after purchasing an additional 1,313,653 shares during the period. Finally, Amundi increased its position in Zoetis by 30.8% during the first quarter. Amundi now owns 3,595,628 shares of the company’s stock worth $575,691,000 after purchasing an additional 846,909 shares during the last quarter. 92.80% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of brokerages have weighed in on ZTS. JPMorgan Chase & Co. decreased their price target on shares of Zoetis from $230.00 to $200.00 and set an “overweight” rating on the stock in a report on Wednesday, November 5th. Morgan Stanley reduced their target price on Zoetis from $211.00 to $175.00 and set an “overweight” rating on the stock in a report on Monday. Leerink Partners downgraded Zoetis from an “outperform” rating to a “market perform” rating and lowered their price target for the company from $180.00 to $155.00 in a research report on Thursday, July 17th. Leerink Partnrs downgraded Zoetis from a “strong-buy” rating to a “hold” rating in a report on Thursday, July 17th. Finally, UBS Group reduced their price objective on Zoetis from $158.00 to $141.00 and set a “neutral” rating on the stock in a research note on Wednesday, November 5th. Five analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $182.50.

Zoetis Trading Up 0.3%

NYSE:ZTS opened at $120.09 on Wednesday. The business’s 50-day moving average is $142.82 and its two-hundred day moving average is $152.16. The firm has a market capitalization of $52.92 billion, a PE ratio of 20.67, a price-to-earnings-growth ratio of 2.31 and a beta of 0.90. Zoetis Inc. has a 12 month low of $117.26 and a 12 month high of $181.85. The company has a debt-to-equity ratio of 1.05, a current ratio of 1.76 and a quick ratio of 1.04.

Zoetis (NYSE:ZTS) last issued its earnings results on Tuesday, November 4th. The company reported $1.70 earnings per share for the quarter, topping the consensus estimate of $1.62 by $0.08. The company had revenue of $2.40 billion during the quarter, compared to the consensus estimate of $2.42 billion. Zoetis had a return on equity of 56.90% and a net margin of 27.83%.The company’s revenue was up .5% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.58 earnings per share. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. Research analysts predict that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 2nd. Stockholders of record on Friday, October 31st will be paid a dividend of $0.50 per share. The ex-dividend date is Friday, October 31st. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.7%. Zoetis’s dividend payout ratio (DPR) is currently 33.67%.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.